HLN
Haleon plcNYSEHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
32.57
PEG
0.41
P/B
2.06
P/S
4.03
EV/EBITDA
19.52
DCF Value
$20.50
FCF Yield
2.8%
Div Yield
1.5%
Margins & Returns
Gross Margin
61.5%
Operating Margin
18.8%
Net Margin
12.6%
ROE
6.4%
ROA
14.8%
ROIC
4.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $5.52B | $855.7M | $0.19 |
| FY 2025 | $10.79B | $1.63B | $0.36 |
| Q2 2025 | $5.48B | $806.0M | $0.18 |
| Q1 2025 | $2.74B | $403.0M | $0.09 |
Analyst Ratings
View AllCompany Info
Sector
Healthcare
Industry
—
Country
GB
Exchange
NYSE
Beta
0.33
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.